logo

CORONA vs ZOTA: Stock Comparison

CORONA REMEDIES vs ZOTA HEALTH CAREUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a higher ROE, a higher dividend yield and a higher ROCE, while ZOTA HEALTH CARE shows a lower P/E, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CORONA leads 6; ZOTA leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CORONAZOTA

Valuation lens

What price are you paying?

Market CapContext only
₹12,313 Cr
₹4,714 Cr
P/E RatioZOTA has the lower reading
61.87x
0x ✓
P/B RatioZOTA has the lower reading
16.49x
6.8x ✓
EPSCORONA has the higher reading
₹9.83 ✓
₹-12.58
Book ValueContext only
₹122.12
₹201.01
Dividend YieldCORONA has the higher reading
0.5% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CORONA is the larger company
₹12,313 Cr vs ₹4,714 Cr
P/E Ratio
ZOTA has a lower P/E
0x vs 61.87x
P/B Ratio
ZOTA has a lower P/B
6.8x vs 16.49x
EPS
CORONA has higher earnings per share
₹9.83 vs ₹-12.58
Dividend Yield
CORONA has a higher dividend yield
0.5% vs 0%
Revenue Growth (TTM YoY)
ZOTA has faster revenue growth
67.7% vs 0%
ROE
CORONA has a higher ROE
24.28% vs -10.64%
ROCE
CORONA has a higher ROCE
20.94% vs -8.71%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCORONAZOTA
Sector—Healthcare
Industry—Pharmaceuticals

Price

MetricCORONAZOTA
Live Price₹2,010₹1,359.9
Day Change0.3%-3.51%
Volume17,44444,643
52-Week High₹2,292.4₹1,740
52-Week Low₹1,336.6₹1,022
Distance from 52W High-12.32%-21.84%

Valuation

MetricCORONAZOTA
Market Cap₹12,313 Cr₹4,714 Cr
P/E Ratio61.87x0x
P/B Ratio16.49x6.8x
EPS₹9.83₹-12.58
Book Value₹122.12₹201.01
Dividend Yield0.5%0%

Growth

MetricCORONAZOTA
Revenue Growth (TTM YoY)0%67.7%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricCORONAZOTA
ROE24.28%-10.64%
ROCE20.94%-8.71%
Net Margin13.19%-13.98%
Operating Margin15.89%-11.6%
Debt to Equity0.19x0.04x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricCORONAZOTA
Promoter Holding69%49.38%
FII Holding4.21%▲ 0.58 pp7.92%▼ 0.29 pp
DII Holding16.45%▲ 3.55 pp6.75%▲ 0.35 pp
Public Holding10.34%▼ 4.14 pp35.96%▼ 0.04 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and ZOTA HEALTH CARE.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.